Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemoradiotherapy – comparison of T category between the American Joint Committee on Cancer and Japan Pancreas Society
HPB · 2023
DOI: 10.1016/j.hpb.2023.06.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2023. Verfasst von Aoi Hayasaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Mie University, Tsu, Mie, Japan. Electronic address: a-hayasaki@med.mie-u.ac.jp. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Adenocarcinoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: T category classification for pancreatic ductal adenocarcinoma (PDAC) in the Classification of Pancreatic Cancer by the Japan Pancreas Society (JPS) is quite different from that of the American Joint Committee on Cancer (AJCC). The JPS classification focuses on extrapancreatic extension, while the AJCC focuses mainly on tumor size. This study aimed at identifying prognostic factors in PDAC patients undergoing chemoradiotherapy (CRT) by comparing the differences of T categories in these two classifications. METHODS: This retrospective study involved 344 PDAC patients who underwent CRT from 2005 to 2019 and their T-category variables were re-evaluated on computed tomography (CT) images. Disease-specific survival (DSS) was compared based on the JPS and AJCC T categories, while multivariate analysis was performed to identify prognostic factors. RESULTS: Based on the AJCC, 5-year DSS of T3 was better than those of T1 and T2 (57.1% vs. 47.7% and 37.4%). In multivariate analysis, performance status, CEA, the involvement of superior mesenteric vein and superior mesenteric artery, the JPS stage before CRT, and regimen of chemotherapy were identified as independent prognostic factors. CONCLUSIONS: In localized PDAC patients treated with chemoradiotherapy, extrapancreatic extension, as while as biological, conditional and therapeutic factors, is a better prognostic factor than tumor size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Mie University, Tsu, Mie, Japan. Electronic address: a-hayasaki@med.mie-u.ac.jp.
- Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Mie University, Tsu, Mie, Japan.
- Department of Radiology, Mie University, Tsu, Mie, Japan.
Zitieren
APA
Hayasaki, A., Mizuno, S., Nagata, M., Kaluba, B., Maeda, K., Shinkai, T., Ito, T., Gyoten, K., Fujii, T., Iizawa, Y., Tanemura, A., Murata, Y., Kuriyama, N., Isaji, S., & Kishiwada, M. (2023). Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemoradiotherapy – comparison of T category between the American Joint Committee on Cancer and Japan Pancreas Society. HPB. https://doi.org/10.1016/j.hpb.2023.06.015
Vancouver
Hayasaki A, Mizuno S, Nagata M, Kaluba B, Maeda K, Shinkai T, et al. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemoradiotherapy – comparison of T category between the American Joint Committee on Cancer and Japan Pancreas Society. HPB. 2023. doi:10.1016/j.hpb.2023.06.015
BibTeX
@article{Hayasaki2023,
author = {Hayasaki, Aoi and Mizuno, Shugo and Nagata, Motonori and Kaluba, Benson and Maeda, Koki and Shinkai, Toru and Ito, Takahiro and Gyoten, Kazuyuki and Fujii, Takehiro and Iizawa, Yusuke and Tanemura, Akihiro and Murata, Yasuhiro and Kuriyama, Naohisa and Isaji, Shuji and Kishiwada, Masashi},
title = {Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemoradiotherapy – comparison of T category between the American Joint Committee on Cancer and Japan Pancreas Society},
journal = {HPB},
year = {2023},
doi = {10.1016/j.hpb.2023.06.015}
}
EUVIMED